INSULET CORPORATION

(PODD)
  Report
Delayed Nasdaq  -  05/18 04:00:01 pm EDT
190.03 USD   -5.00%
05/17Citigroup Adjusts Insulet's Price Target to $310 From $350, Reiterates Buy Rating
MT
05/06JPMorgan Adjusts Price Target for Insulet to $275 From $290, Maintains Overweight Rating
MT
05/06SVB Securities Adjusts Insulet's Price Target to $280 from $300, Keeps Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insulet Shares Rally on FDA Approval of Omnipod 5

01/28/2022 | 10:25am EDT

By Colin Kellaher


Shares of Insulet Corp. rose nearly 10% on Friday after the medical-device company won U.S. Food and Drug Administration approval for its Omnipod 5 automated insulin-delivery system for individuals ages 6 and older with type 1 diabetes.

The FDA nod represents a meaningful milestone for Insulet, said analysts at Citi, who noted that the Acton, Mass., company and its investors have been waiting for a green light for almost a year.

Citi said it believes the Omnipod 5, which is the first tubeless automated insulin-delivery system that integrates with DexCom Inc.'s G6 continuous glucose monitoring system and a compatible smartphone, will be very well received, and the analysts reiterated their buy rating on the stock.

Insulet shares were recently changing hands at $213.12, up 9.4%.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

01-28-22 1025ET

Stocks mentioned in the article
ChangeLast1st jan.
DEXCOM, INC. -7.13% 308.49 Delayed Quote.-42.55%
INSULET CORPORATION -5.00% 190.03 Delayed Quote.-24.82%
All news about INSULET CORPORATION
05/17Citigroup Adjusts Insulet's Price Target to $310 From $350, Reiterates Buy Rating
MT
05/06JPMorgan Adjusts Price Target for Insulet to $275 From $290, Maintains Overweight Ratin..
MT
05/06SVB Securities Adjusts Insulet's Price Target to $280 from $300, Keeps Outperform Ratin..
MT
05/06INSULET CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
05/06INSULET CORP : Change in Directors or Principal Officers, Other Events, Financial Statemen..
AQ
05/05Insulet Reports Q1 Profit , Names New CEO
MT
05/05Insulet Announces CEO Transition
BU
05/05TRANSCRIPT : Insulet Corporation, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Insulet Corporation Announces Management Changes, Effective June 1, 2022
CI
05/05Insulet Corporation Announces Executive Changes, Effective June 1, 2022
CI
More news
Analyst Recommendations on INSULET CORPORATION
More recommendations
Financials (USD)
Sales 2022 1 233 M - -
Net income 2022 93,3 M - -
Net Debt 2022 207 M - -
P/E ratio 2022 143x
Yield 2022 -
Capitalization 13 177 M 13 177 M -
EV / Sales 2022 10,9x
EV / Sales 2023 8,87x
Nbr of Employees 2 300
Free-Float 99,5%
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 190,03 $
Average target price 272,25 $
Spread / Average Target 43,3%
EPS Revisions
Managers and Directors
Shacey Petrovic President, Chief Executive Officer & Director
Wayde Dwight McMillan Chief Financial Officer, Treasurer & Executive VP
Timothy J. Scannell Independent Chairman
Trang Ly Senior Vice President & Medical Director
Charles Alpuche Chief Operations Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INSULET CORPORATION-24.82%13 870
ABBOTT LABORATORIES-19.89%200 553
MEDTRONIC PLC0.12%142 552
BECTON, DICKINSON AND COMPANY2.17%73 051
BAXTER INTERNATIONAL INC.-15.98%37 432
HOYA CORPORATION-26.45%35 518